斑马鱼
脂肪变性
脂肪肝
内分泌学
内科学
罗格列酮
脂滴
生物
炎症
病理生理学
医学
生物化学
糖尿病
疾病
基因
作者
Manoj Singh,Rohit Yadav,Akash Kumar Bhaskar,Shantanu Sengupta,Chetana Sachidanandan
标识
DOI:10.1016/j.bbalip.2022.159246
摘要
Non-alcoholic Fatty Liver Disease (NAFLD) or pathological hepatic lipid overload, is considered to affect obese individuals. However, NAFLD in lean individuals is prevalent, especially in South Asian population. The pathophysiology of lean NAFLD is not well understood and most animal models of NAFLD use the high-fat diet paradigm. To bridge this gap, we have developed a diet-independent model of NAFLD in zebrafish. We have previously shown that chronic systemic inflammation causes metabolic changes in the liver leading to hepatic fat accumulation in an IL6 overexpressing (IL6-OE) zebrafish model. In the present study, we compared the hepatic lipid composition of adult IL6-OE zebrafish to the controls and found an accumulation of saturated triacylglycerols and a reduction in the unsaturated triacylglycerol species reminiscent of NAFLD patients. Zebrafish is an ideal system for chemical genetic screens. We tested whether the hepatic lipid accumulation in the IL6-OE is responsive to chemical treatment. We found that PPAR-gamma agonist Rosiglitazone, known to reduce lipid overload in the high-fat diet models of NAFLD, could ameliorate the fatty liver phenotype of the IL6-OE fish. Rosiglitazone treatment reduced the accumulation of saturated lipids and showed a concomitant increase in unsaturated TAG species in our inflammation-induced NAFLD model. Our observations suggest that the IL6-OE model can be effective for small molecule screening to identify compounds that can reverse hepatic lipid accumulation, especially relevant to lean NAFLD. • Chronic IL6 overexpression causes lipid accumulation in larval zebrafish liver and serves as a diet-independent model for Non-alcoholic Fatty Liver Disease • IL6 overexpressing zebrafish larvae and adult male liver have an increase in saturated triacylglycerols and a reduction of unsaturated triacylglycerols • Rosiglitazone, a PPAR-gamma agonist ameliorates the hepatic lipid accumulation in the zebrafish fatty liver model • Rosiglitazone treatment increases unsaturated triacylglycerols and reduces saturated triacylglycerols in the zebrafish liver
科研通智能强力驱动
Strongly Powered by AbleSci AI